Despite advances in medical therapy and improved access to percutaneous coronary intervention (PCI), the burden of heart failure after acute myocardial infarction (MI) remains high. We aimed to study the beneficial effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular (LV) function in patients with MI and LV dysfunction (ejection fraction < 50%). We studied 72 diabetic patients (50 cases and 22 controls) who were admitted to our hospital with acute MI and underwent primary PCI. The case group received dapagliflozin as part of their diabetes management. Baseline echocardiographic parameters were recorded. The two groups were followed up for a median period of 5 months, with repeat echocardiography being performed at follow-up. Patients receiving dapagliflozin had a decrease in LV mass from pretreatment values of 222–190.8 g, which was statistically significant (p = 0.0003). Similar changes were reflected in the LV mass index, which reduced from 128.67 g/m2 at baseline to 110.9 g/m2 at follow-up (p = 0.0004). The LV ejection fraction by area length method increased from baseline means of 41.56%–45.02%. The control group’s mean LV mass did not show statistically significant change during follow-up. The ejection fraction measured by area length method improved from 44.1%, at baseline to 51.1% at follow-up. In patients with acute MI and LV dysfunction, SGLT2 inhibitors have improved LV remodeling by reducing LV mass and LV mass index with concomitant reductions in the interventricular septum, posterior wall, and relative wall thickness.
Satheesh J, Rao MS, Ramachandran P, Samanth J. Effect of SGLT2 inhibitors on left ventricular function in patients with acute myocardial infarction and left ventricular dysfunction: A single-center randomized study. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2025.206239
1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990- 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59. doi: https://doi.org/10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017;390(10106):e38. doi: https://doi.org/10.1016/S0140-6736(17)32647-8
2. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health. 2017;5(7):e665–72. doi: https://doi.org/10.1016/S2214-109X(17)30196-1
3. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. Arch Intern Med. 2003;163(19):2345–53. doi: https://doi.org/10.1001/archinte.163.19.2345
4. Hellermann JP, Jacobsen SJ, Gersh BJ, Rodeheffer RJ, Reeder GS, Roger VL. Heart failure after myocardial infarction: a review. Am J Med. 2002;113(4):324–30. doi: https://doi.org/10.1016/S0002-9343(02)01185-3
5. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin receptor–neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021;385(20):1845–55. doi: https://doi.org/10.1056/NEJMoa2104508
6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. doi: https://doi.org/10.1056/NEJMoa1504720
7. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323–34. doi: https://doi.org/10.1161/CIRCULATIONAHA.117.032038
8. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018;380(4):347–57. doi: https://doi.org/10.1056/NEJMoa1812389
9. Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure UMIN000019789 UMIN. Cardiovasc Diabetol. 2018;17(1):1–8. doi: https://doi.org/10.1186/s12933-018-0775-z
10. Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. Diabetes Care. 2019;43(Supplement_1):S14–31. doi: https://doi.org/10.2337/dc20-S002
11. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):1321–60. doi: https://doi.org/10.1016/j.echo.2016.01.011
12. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–71. doi: https://doi.org/10.1093/ehjci/jev014
13. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. doi: https://doi.org/10.1161/CIR.0000000000001073
14. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contributio. Eur Heart J. 2021;42(36):3599–726. doi: https://doi.org/10.1093/eurheartj/ehab368
15. Tsampasian V, Elghazaly H, Chattopadhyay R, Ali O, Corballis N, Chousou PA, et al. Sodium glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(6):e227–9. doi: https://doi.org/10.1093/eurjpc/zwab189
16. Lahnwong C, Palee S, Apaijai N, Sriwichaiin S, Kerdphoo S, Jaiwongkam T, et al. Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovasc Diabetol. 2020;19(1):91. doi: https://doi.org/10.1186/s12933-020-01066-9
17. Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73. doi: https://doi.org/10.1186/s12933-018-0717-9
18. Zhang DP, Xu L, Wang LF, Wang HJ, Jiang F. Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2020;19(1):10. doi: https://doi.org/10.1186/s12933-020-0987-x
19. Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation. 2019;140(21):1693–702. doi: https://doi.org/10.1161/CIRCULATIONAHA.119.042375
20. Brown AJM, Gandy S, McCrimmon R, Houston JG, Struthers AD, Lang CC. A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial. Eur Heart J. 2020;41(36):3421–32. doi: https://doi.org/10.1093/eurheartj/ehaa419
21. Sakai T, Miura S. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction - novel prospective cohort study. Circ Rep. 2019;1(7):286–95. doi: https://doi.org/10.1253/circrep.CR-19-0018
22. van Loon RB, Veen G, Kamp O, Baur LHB, van Rossum AC. Left ventricular remodeling after acute myocardial infarction: the influence of viability and revascularization - an echocardiographic substudy of the VIAMI-trial. Trials. 2014;15(1):329. doi: https://doi.org/10.1186/1745-6215-15-329
23. Khattar RS. Effect of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure. Minerva Cardioangiol. 2003;51(2):143–54.
24. Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, et al. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516–25. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.052186
25. Pericas P, Mas-Lladó C, Ramis-Barceló MF, Valadrón I, Noris Mora M, Pasamar Márquez L, et al. Impact of sacubitril–valsartan treatment on diastolic function in patients with heart failure and reduced ejection fraction. High Blood Press Cardiovasc Prev. 2021;28(2):167–75. doi: https://doi.org/10.1007/s40292-021-00437-x
26. Willenheimer R, Rydberg E, Öberg L, Juul-Möller S, Erhardt L. ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function. Eur Heart J. 1999;20(22):1647–56. doi: https://doi.org/10.3390/ijms26052103
27. Piccirillo F, Lanciotti M, Nusca A, Frau L, Spanò A, Liporace P, et al. Sodium-glucose transporter-2 inhibitors (SGLT2i) and myocardial ischemia: another compelling reason to consider these agents regardless of diabetes. Int J Mol Sci. 2025;26(5):2103. doi: https://doi.org/10.3390/ijms26052103
Year
Month